DGAP-News

APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share - Seite 2

APONTIS PHARMA intends to use the proceeds from the issuance of the new shares of EUR 38 million to primarily pursue selected investments in the development of new Single Pills, the acceleration of the development and licensing of its existing short-term product pipeline and the expansion of its marketing and sales activities to capture further market share as well as product acquisitions.

Karlheinz Gast, CEO of APONTIS PHARMA AG: "The strong support of investors for our business model is an important testimony to our Company, our employees and the chronically ill patients who are treated with our Single Pills. It fills us with great confidence and spurs us on to continue creating added value for our patients and employees as well as investors and our Company. We will use the funds raised to bring new Single Pills to market and expand our leadership position. In this way, we contribute to the wealth-building of our society and help prevent medically avoidable, premature deaths every day."

The first day of trading of APONTIS PHARMA's shares on the Frankfurt Stock Exchange (Scale) is scheduled for 11 May 2021 under the international securities identification number (ISIN) DE000A3CMGM5 and the ticker symbol APPH. Settlement with delivery of shares is expected to take place on 12 May 2021.

The purchaser offers submitted via the subscription functionality "DirectPlace(R)" of the Frankfurt Stock Exchange ("Subscription Functionality") were not allocated.

Preferential allocation to the Company's board members or their relatives, or to the Company's employees or business partners did not occur.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.